← Leaderboards
Jagannadha K Sastry
University Of Texas Md Anderson Can Ctr
$8,292,142
Attributed
$10,587,693
Total exposure
8
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2005–24$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$10,587,693 · 8
By mechanism
R01$8,770,631 · 4
R21$1,481,513 · 3
R56$335,549 · 1
Top collaborators
- Faye Johnson5 shared
- Michael A Barry3 shared
- Peter J Hotez2 shared
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponseProteinsMacaca MulattaT-LymphocyteAffectRouteMediatingSiteImmune ResponseImmunizationDendritic CellsSurfaceHuman PapillomavirusMouse ModelMucous MembraneImmunogenicityVaccinationVaccinesAntigensGenesTissuesBaseInfectionAnimal Model
Grant awards (25)
Harnessing Aurora kinase inhibitionâinduced cell death to enhance immunotherapy in HPVâdriven cancers$352,047
R01 · FY2024 · CA
Harnessing Aurora kinase inhibitionâinduced cell death to enhance immunotherapy in HPVâdriven cancers$363,164
R01 · FY2023 · CA
Harnessing Aurora kinase inhibitionâinduced cell death to enhance immunotherapy in HPVâdriven cancers$363,164
R01 · FY2022 · CA
Harnessing Aurora kinase inhibitionâinduced cell death to enhance immunotherapy in HPVâdriven cancers$370,575
R01 · FY2021 · CA
Vaccine Synergy through Synchronous Delivery$741,448
R01 · FY2020 · AI
Harnessing Aurora kinase inhibitionâinduced cell death to enhance immunotherapy in HPVâdriven cancers$370,575
R01 · FY2020 · CA
A novel mucosal trichuriasis vaccine for Th2 immune protection.$240,043
R21 · FY2020 · AI
Vaccine Synergy through Synchronous Delivery$798,766
R01 · FY2019 · AI
A novel mucosal trichuriasis vaccine for Th2 immune protection.$214,260
R21 · FY2019 · AI
Vaccine Synergy through Synchronous Delivery$777,061
R01 · FY2018 · AI
Role of mucosal epithelial cells in HIV infection and pathology$335,549
R56 · FY2010 · AI · contact PI
Alpha-galactosycleramide as a mucosal adjuvant for HIV antigens$192,500
R21 · FY2010 · AI · contact PI
Alpha-galactosycleramide as a mucosal adjuvant for HIV antigens$231,000
R21 · FY2009 · AI · contact PI
Mucosal Immunization with a Conserved HIV Envelope Peptide Cocktail Vaccine$294,399
R21 · FY2007 · AI · contact PI
HIV Envelope Peptide-Based Vaccine in SHIV-Rhesus Model$615,118
R01 · FY2006 · AI · contact PI
Mucosal Immunization with a Conserved HIV Envelope Peptide Cocktail Vaccine$309,311
R21 · FY2006 · AI · contact PI
HIV Envelope Peptide-Based Vaccine in SHIV-Rhesus Model$616,405
R01 · FY2005 · AI
HIV Envelope Peptide-Based Vaccine in SHIV-Rhesus Model$446,498
R01 · FY2004 · AI
HPV SPECIFIC CELLULAR IMMUNITY IN CERVICAL INTRAEPITHELI$451,697
R01 · FY2003 · CA
HPV SPECIFIC CELLULAR IMMUNITY IN CERVICAL INTRAEPITHELI$440,726
R01 · FY2002 · CA
HIV ENVELOPE PEPTIDE BASED VACCINE IN SHIV RHESUS MODEL$356,375
R01 · FY2002 · AI
HIV ENVELOPE PEPTIDE BASED VACCINE IN SHIV RHESUS MODEL$491,375
R01 · FY2001 · AI
HPV SPECIFIC CELLULAR IMMUNITY IN CERVICAL INTRAEPITHELI$429,172
R01 · FY2001 · CA
HPV SPECIFIC CELLULAR IMMUNITY IN CERVICAL INTRAEPITHELI$417,590
R01 · FY2000 · CA
HIV ENVELOPE PEPTIDE BASED VACCINE IN SHIV RHESUS MODEL$368,875
R01 · FY2000 · AI